Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem vs Other Carbapenems for ESBL-Producing Gram-Negative Infections
NCT01297842Phase 4Unknown
- Sponsor
- Mahidol University
- Start
- May 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ertapenem in Gram-negative bacterial infection (2 arms), sponsored by Mahidol University. Primary endpoint: Number of subjects with cure or improvement at 14 days. Status: unknown.
02
Drugs
ertapenem
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT01297842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297842.